Evolent Health, Inc. (NYSE:EVH) Receives $17.71 Consensus Price Target from Analysts

Evolent Health, Inc. (NYSE:EVH - Get Free Report) has received an average recommendation of "Buy" from the fourteen analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $17.71.

Several research analysts recently issued reports on the stock. Truist Financial reduced their price target on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Citigroup decreased their price target on shares of Evolent Health from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. UBS Group lowered their price target on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, January 16th. Royal Bank of Canada decreased their price objective on Evolent Health from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 14th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a research note on Friday, February 21st.

Evolent Health Price Performance

Evolent Health stock traded up $0.78 during trading hours on Wednesday, hitting $10.73. 1,747,176 shares of the stock were exchanged, compared to its average volume of 2,374,724. Evolent Health has a 12 month low of $8.35 and a 12 month high of $33.63. The business's 50-day moving average is $9.48 and its two-hundred day moving average is $12.01. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market capitalization of $1.25 billion, a P/E ratio of -13.09 and a beta of 1.20.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The business had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. Equities research analysts expect that Evolent Health will post 0.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Brendan B. Springstubb purchased 5,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average cost of $8.75 per share, for a total transaction of $43,750.00. Following the transaction, the director now directly owns 11,842 shares of the company's stock, valued at approximately $103,617.50. The trade was a 73.08 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, President Daniel Joseph Mccarthy acquired 11,040 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were purchased at an average price of $9.01 per share, with a total value of $99,470.40. Following the acquisition, the president now owns 389,004 shares of the company's stock, valued at approximately $3,504,926.04. This trade represents a 2.92 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 74,000 shares of company stock worth $666,315. Insiders own 1.60% of the company's stock.

Institutional Trading of Evolent Health

Several hedge funds have recently added to or reduced their stakes in the business. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Evolent Health during the 4th quarter worth approximately $26,000. R Squared Ltd bought a new position in shares of Evolent Health during the fourth quarter worth approximately $31,000. AlphaQuest LLC boosted its position in shares of Evolent Health by 21,650.0% in the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after acquiring an additional 3,031 shares during the period. Parkside Financial Bank & Trust boosted its holdings in Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after purchasing an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in Evolent Health during the fourth quarter worth approximately $61,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.